• 1
    Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin. LiverDis. 1994; 14: 7181.
  • 2
    Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 16476.
  • 3
    Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin. LiverDis. 1997; 17: 23347.
  • 4
    Moore K. The hepatorenal syndrome. Clin. Sci. 1997; 92: 43343.
  • 5
    Moreau R, Durand F, Poynard T et al. Predictive factors of improved renal function and survival in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin. A retrospective multicenter study. Gastroenterology 2002, in press.
  • 6
    Stanley MM, Ochi S, Lee KK et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N. Engl. J. Med. 1989; 321: 16328.
  • 7
    Ginès A, Escorsell A, Ginès P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 22936.
  • 8
    Thadani R, Pascual M, Bonventre JV. Acute renal failure. N. Engl. J. Med. 1996; 334: 144860.
  • 9
    Klahr S, Miller SB. Acute oliguria. N. Engl. J. Med. 1998; 338: 6715.
  • 10
    Diamond JR, Yoburn DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium. Ann. Intern. Med. 1982; 96: 597600.
  • 11
    Fernandez-Seara J, Prieto J, Quiroga J et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 130412.
  • 12
    Guarner C, Soriano G, Tomas A et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 113943.
  • 13
    Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J. Hepatol. 1995; 23: 21824.
  • 14
    Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104: 17504.
  • 15
    Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin. Invest. 1999; 104: 122333.
  • 16
    Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N. Engl. J. Med. 1992; 327: 17748.
  • 17
    Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Toxicol. 2001; 41: 85176.
  • 18
    Soper CPR, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347: 18423.
  • 19
    Cardenas A, Gines P, Uriz J et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34: 6716.
  • 20
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 163748.
  • 21
    Gonwa TA, Klintmalm GB, Levy M, Jennings LD, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 3615.
  • 22
    Short A, Cumming A. Renal support. Br. Med. J. 1999; 319: 414.
  • 23
    Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000; 6: 27786.
  • 24
    Vanholder R, Van Biesen W, Lameire N. What is the renal replacement method of first choice for intensive care patients? J. Am. Soc. Nephrol. 2001; 12 (Suppl. 17): S403.
  • 25
    Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J. Hepatol. 1990; 11: 1538.
  • 26
    Ginès A, Salmeron JM, Ginès P et al. Oral misoprosotol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J. Hepatol. 1993; 17: 2206.
  • 27
    Arieff AI, Chidsey CA. Renal function in cirrhosis and the effects of prostaglandin A1. Am. J. Med. 1974; 56: 695703.
  • 28
    Zussman RM, Axelrod L, Tolkoff-Rubin N. The treatment of hepatorenal syndrome with intrarenal administration of prostaglandin E1. Prostaglandins 1977; 13: 81930.
  • 29
    Barnardo DE, Baldus WP, Maher FT. Effects of dopamine on renal function in patients with cirrhosis. Gastroenterology 1970; 58: 52431.
  • 30
    Bacq Y, Gaudin C, Hadengue A et al. Systemic, splanchnic, and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology 1991; 14: 4837.
  • 31
    Linas SL, Schaeffer JW, Moore EE, Good JT Jr, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int. 1986; 30: 73640.
  • 32
    Daskalopoulos G, Jordan DR, Reynolds TB. Randomized trial of peritoneovenous shunt (PVS) in the treatment of hepatorenal syndrome (HRS). Gastroenterology 1995; 88: 88 (Abstract).
  • 33
    Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 26472.
  • 34
    Epstein M. Role of the peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. In: Epstein M, ed. The Kidney in Liver Disease, 3th edn. Baltimore: Williams & Wilkins, 1988; 593612.
  • 35
    Richter GM, Noeldge G, Palmaz JC et al. Transjugular intrahepatic portacaval stent shunt: preliminary clinical results. Radiology 1990; 174: 102730.
  • 36
    Guevara M, Ginès P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 41622.
  • 37
    Brensing KA, Textor J, Perz J et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 28895.
  • 38
    Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 6469.
  • 39
    Lebrec D, Giuily N, Hadengue A et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites. A randomized trial. J. Hepatol. 1996; 25: 13544.DOI: 10.1016/S0168-8278(96)80065-1
  • 40
    Nazarian GK, Bjarnason H, Dietz CA et al. Refractory ascites: midterm results of treatment with a transjugular intrahepatic portosystemic shunt. Radiology 1997; 205: 17380.
  • 41
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 86471.
  • 42
    Lake JR. The role of transjugular portosystemic shunting in patients with ascites. N. Engl. J. Med. 2000; 342: 17457.
  • 43
    Holt S, Goodier D, Marley R et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999; 353: 2945.
  • 44
    Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 16907.
  • 45
    Duvoux C, Zanditenas D, Hézode C et al. Noradrenaline for treatment of type 1 hepatorenal syndrome (HRS). J. Hepatol. 2001; 34 (Suppl. 1): 18 (Abstract).
  • 46
    Lenz K, Hortnagel H, Druml W et al. Ornipressin in the treatment of functional renal failure in decompensated cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 10607.
  • 47
    Guevara M, Ginès P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 3541.
  • 48
    Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 8705.
  • 49
    Fachinformation. Glycylpressin R, terlipressin acetate. Kiel: Ferring Arzneimittel GmbH, 1996 (In German).
  • 50
    Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig. Dis. Sci. 1996; 41: 10546.
  • 51
    Cervoni JP, Lecomte T, Cellier C et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am. J. Gastroenterol. 1997; 92: 211314.
  • 52
    Le Moine O, El Nawar A, Jagodzinski R et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol. Belg. 1998; 61: 26870.
  • 53
    Hadengue A, Gadano A, Moreau R et al. Beneficial effects of the two-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. 1998; 29: 56570.DOI: 10.1016/S0168-8278(98)80151-7
  • 54
    Uriz J, Ginès P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J. Hepatol. 2000; 33: 3348.
  • 55
    Gines P, Ortega R, Uriz J et al. Effects of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase-II study. Hepatology 2001; 34 (2): 186A (Abstract).
  • 56
    Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J. Hepatol. 2000; 32: 14253.DOI: 10.1016/S0168-8278(00)80201-9
  • 57
    De Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J. Hepatol. 2000; 3: 84652.
  • 58
    Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin. Liver Dis. 1997; 17: 20316.
  • 59
    Runyon BA. Albumin infusion for spontaneous bacterial peritonitis. Lancet 1999; 354: 8389.
  • 60
    Follo A, Llovet JM, Navasa M et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495501.
  • 61
    Navasa M, Follo A, Filella X et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 122732.
  • 62
    Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 10942.
  • 63
    Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 1999; 341: 4039.